Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Han

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2020
Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticlesTom Haber, Yvonne R Cornejo, Soraya Aramburo, et al.
Cancer Letters|December 29, 2014
Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cellsYujun Wang, Ernest Han, Quanhua Xing, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2019
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C Cristea, Paul Frankel, Timothy Synold, et al.
Pleura and Peritoneum|March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progressVinita Popat, Paul H Frankel, Nora H Ruel, et al.
Gynecologic Oncology|January 23, 2024
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancerMihaela C Cristea, Daphne Stewart, Timothy Synold, et al.
Antioxidants (Basel, Switzerland)|April 14, 2025
The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol AcetateRosemary N Senguttuvan, Hyejin Cho, Xiwei Wu, et al.
Antioxidants (Basel, Switzerland)|December 30, 2025
Correction: Senguttuvan et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. <i>Antioxidants</i> 2025, <i>14</i>, 345Rosemary N Senguttuvan, Hyejin Cho, Xiwei Wu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Uterine neoplasms, version 1.2014Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Cervical Cancer, Version 2.2015Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Cervical cancerWui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Proceedings of the National Academy of Sciences of the United States of America|August 1, 2020
Specific targeting of ovarian tumor-associated macrophages by large, anionic nanoparticlesTom Haber, Yvonne R Cornejo, Soraya Aramburo, et al.
Cancer Letters|December 29, 2014
Baicalein upregulates DDIT4 expression which mediates mTOR inhibition and growth inhibition in cancer cellsYujun Wang, Ernest Han, Quanhua Xing, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2019
A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavityMihaela C Cristea, Paul Frankel, Timothy Synold, et al.
Pleura and Peritoneum|March 23, 2026
Multicenter dose de-escalation phase I trial of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) nab-paclitaxel and cisplatin in combination with systemic nab-paclitaxel in recurrent ovarian cancer patients: trial in progressVinita Popat, Paul H Frankel, Nora H Ruel, et al.
Gynecologic Oncology|January 23, 2024
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancerMihaela C Cristea, Daphne Stewart, Timothy Synold, et al.
Antioxidants (Basel, Switzerland)|April 14, 2025
The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol AcetateRosemary N Senguttuvan, Hyejin Cho, Xiwei Wu, et al.
Antioxidants (Basel, Switzerland)|December 30, 2025
Correction: Senguttuvan et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. <i>Antioxidants</i> 2025, <i>14</i>, 345Rosemary N Senguttuvan, Hyejin Cho, Xiwei Wu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Uterine neoplasms, version 1.2014Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 15, 2015
Cervical Cancer, Version 2.2015Wui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Cervical cancerWui-Jin Koh, Benjamin E Greer, Nadeem R Abu-Rustum, et al.
Pageof 4